Our Mission >>
The virtual symposium “Reaching Therapeutic Goals in Type 2 Diabetes: New Options” will be held in conjunction with the 55th Congress of the German Diabetes Society (DDG) on May 13, 2021 at 08.30 CET. This 90-minute program will feature Drs. Petra-Maria Schumm-Draeger (Munich) and Andrew J.M. Boulton (Manchester) as co-chairs, leading a vibrant discussion and presentations by Drs. Brian Frier (Edinburgh), Paolo Pozzilli (Rome), and Oliver Schnell (Munich-Neuherberg).
Click here to register for the congress and attend our program.
Click here to learn more about the program.
“Reaching Therapeutic Goals in Type 2 Diabetes” was held as a live webinar on January 27, 2021 and is now available on-demand. This webinar features prominent international speakers from England, India, and Kuwait, and a lively question and answer session. We invite you to participate in this virtual program as well as read the live webinar blog posts written by the speakers. The posts contain current information about proven approaches to preventing hypoglycemia, fixed dose combination treatments in managing type 2 diabetes, the impact of uncontrolled diabetes on overall cardiovascular health, the challenges in treating the global burden of diabetes, and how to optimize type 2 diabetes treatment results amidst the COVID-19 pandemic.
Click here to view the program details.
Click here to register and access the on-demand webinar.
Click here to read the blogs.
Worldwide Diabetes held a live webinar on November 28, 2020 in conjunction with the 34th Congresso Brasileiro de Endocrinolgia e Metabologia (a virtual event). “Advancing Strategies in the Management of Type 2 Diabetes” featured speakers from Belgium, Brazil, England, and the United States and included presentations on preventing hypoglycemia, new uses of insulin, the psychological aspects of patient adherence, and how recent results of cardiovascular outcomes trials point to new treatment options. The webinar is now available on demand.
Click here to view the program.
Due to recent FDA guidelines, there have been many clinical trials that have demonstrated the cardiovascular safety of various antihyperglycemic medications. In this month’s column, Dr. Chan takes a closer look at sodium glucose transporter-2 (SGLT-2) inhibitors, outlining not only their antihyperglycemic effects but also the associated cardiovascular and renal benefits. Please take a moment to read her column and check back here for her continuing editorial contributions.
Click here to read the column.
Click here for Dr. Chan’s previous columns.
Worldwide Cardio Diabetes held a virtual symposium during the recent 7th International Conference on Prehypertension, Hypertension, Metabolic Disorders and Cardiovascular Disease and it is now available on demand. “Diabetes and CardioRenal Disease: Can We Reduce the Impact of this Deadly Combination” features presentations by Drs. Andrew Boulton, George Bakris, Martin Rutter, and Philip Home, delving into the important topics of the kidney and cardiovascular risk, treating heart failure, and improving outcomes in diabetes beyond glucose control therapies.